Holen Sie sich die Stockscreener-App
4.89
2.78%
-0.14
Handel nachbörslich:
4.98
0.09
+1.84%
Schlusskurs vom Vortag:
$5.03
Offen:
$4.99
24-Stunden-Volumen:
289.63K
Relative Volume:
0.71
Marktkapitalisierung:
$47.87M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
-6.6081
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
+29.02%
1M Leistung:
+26.03%
6M Leistung:
-52.80%
1J Leistung:
-79.28%
1-Tages-Spanne:
$4.80
$5.1599
1-Wochen-Bereich:
$3.71
$5.42
52-Wochen-Spanne:
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.89 | 47.87M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumpsbluebird bio (NASDAQ:BLUE) - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
New suitor emerges for struggling bluebird bio - FirstWord Pharma
Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma
bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus
bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha
Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India
Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
bluebird bio receives higher acquisition offer from Ayrmid By Investing.com - Investing.com South Africa
Bluebird bio reports another acquisition offer for $45M upfront - The Business Journals
Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours - Marketscreener.com
Bluebird bio stock rises on new acquisition proposal By Investing.com - Investing.com South Africa
Bluebird bio stock rises on new acquisition proposal - Investing.com
Bluebird Bio confirms receipt non-binding proposal from Ayrmid - TipRanks
Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid - Marketscreener.com
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
Sickle Cell Treatment Market Business Outlook and Growth - openPR
bluebird bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
T-Cell Immunotherapy Market is Booming Worldwide |Medigene,Bluebird Bio,Novartis - openPR
Sickle Cell Disease Treatment Market: New Drug Approvals - openPR
Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE - Business Wire
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Reuters
Drug developers show mixed performance in early 2025 - BioWorld Online
Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials - openPR
Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire
Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld Online
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - Defense World
Stem Cell Therapy Market Growth | Trends, Size & Forecast - openPR
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):